Orchestra BioMed Net Worth
Orchestra BioMed Net Worth Breakdown | OBIO |
Orchestra BioMed Net Worth Analysis
Orchestra BioMed's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Orchestra BioMed's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Orchestra BioMed's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Orchestra BioMed's net worth analysis. One common approach is to calculate Orchestra BioMed's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Orchestra BioMed's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Orchestra BioMed's net worth. This approach calculates the present value of Orchestra BioMed's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Orchestra BioMed's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Orchestra BioMed's net worth. This involves comparing Orchestra BioMed's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Orchestra BioMed's net worth relative to its peers.
To determine if Orchestra BioMed is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Orchestra BioMed's net worth research are outlined below:
| Orchestra BioMed generated a negative expected return over the last 90 days | |
| Orchestra BioMed has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.76 M. Net Loss for the year was (49.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Orchestra BioMed generates negative cash flow from operations | |
| About 22.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Pivots Trading Plans and Risk Controls - Stock Traders Daily |
Orchestra BioMed uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Orchestra BioMed Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Orchestra BioMed's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Orchestra BioMed's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 211.74 M.Market Cap |
|
Project Orchestra BioMed's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.52) | (0.54) | |
| Return On Capital Employed | (0.61) | (0.64) | |
| Return On Assets | (0.52) | (0.54) | |
| Return On Equity | (0.72) | (0.69) |
When accessing Orchestra BioMed's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Orchestra BioMed's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Orchestra BioMed's profitability and make more informed investment decisions.
Evaluate Orchestra BioMed's management efficiency
Orchestra BioMed Holdings has return on total asset (ROA) of (0.392) % which means that it has lost $0.392 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9166) %, meaning that it created substantial loss on money invested by shareholders. Orchestra BioMed's management efficiency ratios could be used to measure how well Orchestra BioMed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.54. In addition to that, Return On Capital Employed is likely to drop to -0.64. At this time, Orchestra BioMed's Other Current Assets are very stable compared to the past year. As of the 26th of November 2024, Fixed Asset Turnover is likely to grow to 1.87, while Total Assets are likely to drop about 66.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.05 | 2.15 | |
| Tangible Book Value Per Share | 2.05 | 2.15 | |
| Enterprise Value Over EBITDA | (5.36) | (5.63) | |
| Price Book Value Ratio | 4.46 | 4.68 | |
| Enterprise Value Multiple | (5.36) | (5.63) | |
| Price Fair Value | 4.46 | 4.68 | |
| Enterprise Value | 274.5 M | 166.5 M |
The operational strategies employed by Orchestra BioMed management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 55.0037 | Revenue 2.6 M | Quarterly Revenue Growth 1.356 | Revenue Per Share 0.073 | Return On Equity (0.92) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Orchestra BioMed insiders, such as employees or executives, is commonly permitted as long as it does not rely on Orchestra BioMed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Orchestra BioMed insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Orchestra BioMed Corporate Filings
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 26th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 30th of July 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Orchestra BioMed Earnings per Share Projection vs Actual
Orchestra BioMed Corporate Management
| Yuval DSc | GM Therapies | Profile | |
| George Papandreou | Senior Therapies | Profile | |
| Avraham MD | Senior Innovation | Profile | |
| Andrew MBA | Chief Officer | Profile | |
| HansPeter MD | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 0.073 | Quarterly Revenue Growth 1.356 | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.